This has been successfully performed with the MYC-inhibitor peptide H1 to inhibit MYC transcription at a nanomolar concentration and to induce lymphoma cell killing, suggesting an interesting novel therapeutic principle against lymphoma (159). This evidence concerns the gene MYC and lymphoma.